Scholar Rock , a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
Scholar Rock (SRRK) stock's buy rating reiterated with $97 target on rising apitegromab approval odds; phase 3 data broadens ...
Biohaven Ltd. today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San ...
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback